Severe COVID-19, multisystem inflammatory syndrome in children, and Kawasaki disease : immunological mechanisms, clinical manifestations and management

Multisystem inflammatory syndrome (MIS-C) is a pediatric hyperinflammation disorder caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). It has now been reported from several countries the world over. Some of the clinical manifestations of MIS-C mimic Kawasaki disease (KD) shock syndrome. MIS-C develops 4-6 weeks following SARS-CoV-2 infection, and is presumably initiated by adaptive immune response. Though it has multisystem involvement, it is the cardiovascular manifestations that are most prominent. High titres of anti-SARS-CoV-2 antibodies are seen in these patients. As this is a new disease entity, its immunopathogenesis is not fully elucidated. Whether it has some overlap with KD is still unclear. Current treatment guidelines recommend use of intravenous immunoglobulin and high-dose corticosteroids as first-line treatment. Mortality rates of MIS-C are lower compared to adult forms of severe COVID-19 disease.

Media Type:

Electronic Article

Year of Publication:

2021

Contained In:

Rheumatology international - Vol. 41, No. 1 (2021), p. 19-32

Language:

English

Contributors:

Kabeerdoss, Jayakanthan
Pilania, Rakesh Kumar
Karkhele, Reena
Kumar, T Sathish
Danda, Debashish
Singh, Surjit

Urls:

Volltext

Keywords:

Coronavirus disease 2019
Hyperinflammation
Journal Article
Kawasaki disease (KD)
Kawasaki-like disease
Multisystem inflammatory syndrome (MIS-C)
Review

Notes:

Date Revised 15.01.2021

published: Print-Electronic

Citation Status In-Process

Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Physical Description:

Online-Ressource

doi:

10.1007/s00296-020-04749-4

PMID:

33219837

PPN (Catalogue-ID):

NLM31886245X